Journal
JOURNAL OF UROLOGY
Volume 185, Issue 4, Pages 1246-1254Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.juro.2010.11.079
Keywords
high-intensity focused ultrasound ablation; magnetic resonance imaging; biopsy; prostatic neoplasms
Categories
Funding
- Medical Research Council (United Kingdom)
- Pelican Cancer Foundation (charity)
- Prostate Research Campaign United Kingdom (charity)
- Prostate Cancer Research Centre at University College London
- St. Peters Trust
- United Kingdom National Institute of Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre
- Cancer Research United Kingdom
- Medical Research Council [G1002509, G0701302] Funding Source: researchfish
- MRC [G1002509, G0701302] Funding Source: UKRI
Ask authors/readers for more resources
Purpose: Men with localized prostate cancer currently face a number of treatment options that treat the entire prostate. These can cause significant sexual and urinary side effects. Focal therapy offers a novel strategy that targets the cancer rather than the prostate in an attempt to preserve tissue and function. Materials and Methods: A prospective, ethics committee approved trial was conducted to determine the side effects of focal therapy using high intensity focused ultrasound. Multiparametric magnetic resonance imaging (T2-weighted, dynamic contrast enhanced, diffusion-weighted) and template transperineal prostate mapping biopsies were used to identify unilateral disease. Genitourinary side effects and quality of life outcomes were assessed using validated questionnaires. Posttreatment biopsies were performed at 6 months and followup was completed to 12 months. Results: A total of 20 men underwent high intensity focused ultrasound hemiablation. Mean age was 60.4 years (SD 5.4, range 50 to 70) with mean prostate specific antigen 7.3 ng/ml (SD 2.8, range 3.4 to 11.8). Of the men 25% had low risk and 75% had intermediate risk cancer. Return of erections sufficient for penetrative sex occurred in 95% of men (19 of 20). In addition, 90% of men (18 of 20) were pad-free, leak-free continent while 95% were pad-free. Mean prostate specific antigen decreased 80% to 1.5 ng/ml (SD 1.3) at 12 months. Of the men 89% (17 of 19, 1 refused biopsy) had no histological evidence of any cancer, and none had histological evidence of high volume or Gleason 7 or greater cancer in the treated lobe. In addition, 89% of men achieved the trifecta status of pad-free, leak-free continence, erections sufficient for intercourse and cancer control at 12 months. Conclusions: Our results appear sufficiently promising to support the further evaluation of focal therapy as a strategy to decrease some of the harms and costs associated with standard whole gland treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available